Welcome to our dedicated page for Inspire Medical SEC filings (Ticker: INSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on minimally invasive neurostimulation therapy for moderate to severe obstructive sleep apnea. These documents offer detailed insight into how Inspire reports its financial results, risks, and corporate developments.
Annual reports on Form 10-K and quarterly reports on Form 10-Q contain management’s discussion and analysis of financial condition and results of operations, along with risk factor disclosures. In these filings, Inspire describes its dependence on Inspire therapy for revenues, coverage and reimbursement considerations, competition from other therapies and technologies, reliance on third-party suppliers and contract manufacturers, international operations, information technology and cybersecurity risks, and other factors that may affect future performance.
Current reports on Form 8-K document specific material events. Recent 8-K filings have covered quarterly and annual financial results, preliminary and unaudited revenue ranges, expectations regarding the release of valuation allowances on U.S. deferred tax assets, authorization of share repurchase programs, and leadership changes such as the transition and appointment of the Chief Financial Officer. These filings often incorporate press releases and investor presentation materials by reference.
Investors can also review compensatory arrangements and executive employment agreements described in 8-K items, which outline base salary, bonus targets, equity awards, severance terms, and change-of-control provisions for senior executives. Such disclosures provide transparency into Inspire’s governance and incentive structures.
On Stock Titan, Inspire’s SEC filings are updated as they are made available on EDGAR. AI-powered summaries highlight key points from lengthy documents, helping readers quickly identify themes such as revenue drivers tied to Inspire therapy, guidance ranges, risk factors, and notable corporate actions, without replacing the need to consult the full official filings.
Inspire Medical Systems, Inc. expects to release a significant portion of the valuation allowance on its U.S. deferred tax assets in the fourth quarter of fiscal 2025. The company estimates this action will create an income tax benefit of $90 million to $100 million for the year. This tax benefit is expected to increase diluted earnings per share by approximately $3.00 to $3.30 for the same period. These figures are based on current assumptions and are described as forward-looking, with actual results potentially differing due to various risks and uncertainties discussed in the company’s other regulatory filings.
Inspire Medical Systems (INSP): Schedule 13G/A update — Dragoneer Investment Group, LLC and Marc Stad filed Amendment No. 1 reporting beneficial ownership of the company’s common stock at 0 shares, representing 0% of the class.
The filing notes ownership of 5 percent or less and lists no voting or dispositive power. The certification states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The date of event is 09/30/2025.
Inspire Medical Systems, Inc. (INSP) disclosed that investment entities affiliated with Deerfield, including Deerfield Mgmt, L.P., Deerfield Management Company, L.P., Deerfield Partners, L.P., and individual investor James E. Flynn, have each reported beneficial ownership of the same block of 1,476,303 shares of Inspire Medical common stock. This position represents 5.08% of the company’s outstanding common stock.
The Deerfield entities and Flynn report shared voting and dispositive power over all 1,476,303 shares and no sole voting or dispositive power. They also certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Inspire Medical, indicating a passive investment stance under the Schedule 13G framework.
Wasatch Advisors LP filed Amendment No. 1 to Schedule 13G for Inspire Medical Systems (INSP), reporting beneficial ownership of 135,914 common shares, representing 0.5% of the class as of September 30, 2025.
The firm holds sole voting and sole dispositive power over all reported shares. It certified the holdings were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control.
Inspire Medical Systems reported Q3 2025 growth with lower profitability. Revenue rose to $224.5 million from $203.2 million as U.S. sales remained the core driver. Gross profit reached $192.7 million, but higher operating costs, including advertising and SG&A, reduced operating income to $9.6 million from $14.3 million.
Net income was $9.9 million versus $18.5 million a year ago, with diluted EPS of $0.34 versus $0.60. For the first nine months, revenue was $642.9 million and net income was $9.3 million. Cash and cash equivalents were $112.8 million, with $209.7 million in short-term investments. Inventories increased to $141.8 million from $80.1 million, reflecting production and demand planning.
The company continued capital returns: it completed an accelerated share repurchase totaling 409,043 shares at an average price of $190.29, repurchased 442,649 shares for $75.0 million earlier in 2025, and bought 552,423 shares for $50.0 million under a new $200.0 million program, leaving $150.0 million authorized. Shares outstanding were 29,053,367 at September 30, 2025.
Inspire Medical Systems reported that it issued a press release announcing financial results for the quarter ended September 30, 2025, and furnished an investor presentation for upcoming meetings with investors and analysts.
The materials are provided as Exhibits 99.1 (press release) and 99.2 (presentation). The company noted these items are furnished, not filed, under the Exchange Act. The investor presentation is also available on the company’s Investor Relations website.
BlackRock, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Inspire Medical Systems (INSP). As of September 30, 2025, BlackRock beneficially owned 3,353,407 shares of INSP, representing 11.3% of the common stock. The filing lists sole voting power over 3,283,122 shares and sole dispositive power over 3,353,407 shares, with no shared voting or dispositive power.
BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF has an interest in INSP common stock that is more than five percent of the total outstanding shares.
Inspire Medical Systems (INSP) reported an insider transaction by a director. On 10/14/2025, the director acquired 229 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this transaction, the director beneficially owns 3,986 shares, held directly.
Inspire Medical Systems (INSP) director Casey M. Tansey reported an equity award. On 10/14/2025, Tansey acquired 221 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.
Following this transaction, Tansey beneficially owned 22,235 shares directly. Additional indirect holdings reported include 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.
Inspire Medical Systems (INSP) director Gary L. Ellis reported acquiring 372 shares of common stock on October 14, 2025. The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reported price of $78.84 per share.
Following this transaction, Ellis beneficially owns 6,454 shares, held directly. This filing reflects routine director compensation settled in stock rather than cash.